Sales of the original Paclitaxel anti-cancer drug 'Taxol' increased 53% in one year. This change has seemed to have occurred as Boryung took over domestic sales from the beginning of this year.

According to IQVIA, a pharmaceutical market research institute, on the 2nd, Taxol's sales in the first quarter was KRW 2.9 billion. This is a 53% increase from KRW 1.9 billion in the first quarter of last year.

Taxol is a paclitaxel-based cytotoxic anti-cancer drug, and is widely used in various types of cancer such as ovarian cancer, breast cancer, lung cancer, and stomach cancer. Despite having been nearly 30 years since it was approved in Korea in 1996, and is still widely used.